Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for Attention Deficits in Mild Huntington Disease
NCT00368849Phase 2Completed
- Sponsor
- University of Iowa
- Start
- Nov 2005
- Primary completion
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Huntington disease (HD) comparing Atomoxetine with Placebo (2 arms). Primary endpoints: Conners' Adult Attention Rating Scale at 4 weeks, Attention Composite Score at 4 weeks and 1 more. Started Nov 2005; status: completed.
02
Drugs
atomoxetine
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NCT00368849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00368849.